Madrigal Pharmaceuticals (MDGL) Retained Earnings (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Retained Earnings data on file, last reported at -$2.2 billion in Q1 2026.

• On a quarterly basis, Retained Earnings fell 561759.9% year-over-year to -$2.2 billion in Q1 2026; TTM through Mar 2026 was -$2.2 billion, a 561759.9% decrease from a year earlier, with the FY2025 full-year figure at $873000.0, up 86.54% from the prior year.
• Retained Earnings for Q1 2026 stood at -$2.2 billion, down from $873000.0 in the prior quarter.
• Over the last five years, Retained Earnings for MDGL reached as high as $1.1 million in Q3 2025 and fell as low as -$2.2 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$795.6 million across 5 years, with a median of -$876.8 million in 2022.
• Across the five-year window, Retained Earnings sank 4175837.5% in 2023 and surged 100.06% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$32000.0 in 2022, then sank by 4175837.5% to -$1.3 billion in 2023, then jumped by 100.04% to $468000.0 in 2024, then surged by 86.54% to $873000.0 in 2025, then plunged by 250369.99% to -$2.2 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$2.2 billion in Q1 2026, $873000.0 in Q4 2025, and $1.1 million in Q3 2025.